Do analysts prefer NEPH or QNRX?

Nephros currently has a consensus price target of $6.00, suggesting a potential upside of 81.82%. Given Nephros' stronger consensus rating and higher possible upside, equities research analysts clearly believe Nephros is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor NEPH or QNRX?

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 1 mentions for Nephros. Nephros' average media sentiment score of 0.03 beat Quoin Pharmaceuticals' score of 0.00 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NSPR or QNRX?

InspireMD presently has a consensus target price of $4.50, suggesting a potential upside of 541.94%. Given InspireMD's stronger consensus rating and higher probable upside, research analysts clearly believe InspireMD is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor NSPR or QNRX?

In the previous week, InspireMD and InspireMD both had 2 articles in the media. InspireMD's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InspireMD 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend QNRX or MLSS?

Milestone Scientific has a consensus target price of $1.00, indicating a potential upside of 235.35%. Given Milestone Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Milestone Scientific is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Milestone Scientific 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate PSTV or QNRX?

Plus Therapeutics currently has a consensus price target of $56.40, indicating a potential upside of 1,282.35%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor PSTV or QNRX?

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend QNRX or CTSO?

Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,152.91%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to QNRX or CTSO?

In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 2 articles in the media. Cytosorbents' average media sentiment score of 0.64 beat Quoin Pharmaceuticals' score of 0.00 indicating that Cytosorbents is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quoin Pharmaceuticals (QNRX) Competitors

$3.25 -1.16 (-26.30%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$4.47 +1.23 (+37.69%)

As of 05:30 AM Eastern

Compare

QNRX vs. NEPH, NSPR, MLSS, PSTV, and CTSO

Should you buy Quoin Pharmaceuticals stock or one of its competitors? MarketBeat compares Quoin Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quoin Pharmaceuticals include Nephros (NEPH), InspireMD (NSPR), Milestone Scientific (MLSS), Plus Therapeutics (PSTV), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.

How does Quoin Pharmaceuticals compare to Nephros?

Nephros (NASDAQ:NEPH) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Nephros has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 1 mentions for Nephros. Nephros' average media sentiment score of 0.03 beat Quoin Pharmaceuticals' score of 0.00 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nephros has a net margin of 4.06% compared to Quoin Pharmaceuticals' net margin of 0.00%. Nephros' return on equity of 7.66% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

41.1% of Nephros shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 6.7% of Nephros shares are held by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nephros currently has a consensus price target of $6.00, suggesting a potential upside of 81.82%. Given Nephros' stronger consensus rating and higher possible upside, equities research analysts clearly believe Nephros is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nephros has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$19.12M	1.87	$1.19M	$0.07	47.14
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Summary

Nephros beats Quoin Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to InspireMD?

InspireMD (NYSE:NSPR) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Quoin Pharmaceuticals has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

InspireMD presently has a consensus target price of $4.50, suggesting a potential upside of 541.94%. Given InspireMD's stronger consensus rating and higher probable upside, research analysts clearly believe InspireMD is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quoin Pharmaceuticals has lower revenue, but higher earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.85M	3.03	-$19.92M	-$0.73	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 34.1% of InspireMD shares are owned by insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

InspireMD has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

In the previous week, InspireMD and InspireMD both had 2 articles in the media. InspireMD's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InspireMD	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InspireMD beats Quoin Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Milestone Scientific has higher revenue and earnings than Quoin Pharmaceuticals. Milestone Scientific is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Milestone Scientific	$8.90M	2.96	-$6.93M	-$0.05	N/A

Milestone Scientific has a consensus target price of $1.00, indicating a potential upside of 235.35%. Given Milestone Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Milestone Scientific is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 0 mentions for Milestone Scientific. Quoin Pharmaceuticals' average media sentiment score of 0.00 equaled Milestone Scientific'saverage media sentiment score.

Company	Overall Sentiment
Quoin Pharmaceuticals	Neutral
Milestone Scientific	Neutral

Quoin Pharmaceuticals has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Milestone Scientific has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Milestone Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Milestone Scientific's net margin of -52.01%. Milestone Scientific's return on equity of -60.26% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Milestone Scientific	-52.01%	-60.26%	-40.23%

Summary

Milestone Scientific beats Quoin Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Plus Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

Plus Therapeutics currently has a consensus price target of $56.40, indicating a potential upside of 1,282.35%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quoin Pharmaceuticals has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.39	-$22.39M	-$2.30	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Plus Therapeutics and Quoin Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Cytosorbents?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Cytosorbents has higher revenue and earnings than Quoin Pharmaceuticals. Cytosorbents is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Cytosorbents	$37.06M	0.73	-$8.20M	-$0.19	N/A

In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 2 articles in the media. Cytosorbents' average media sentiment score of 0.64 beat Quoin Pharmaceuticals' score of 0.00 indicating that Cytosorbents is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quoin Pharmaceuticals has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Cytosorbents	-31.85%	-235.57%	-37.88%

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,152.91%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quoin Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Summary

Cytosorbents beats Quoin Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Quoin Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNRX vs. The Competition

Export

Metric	Quoin Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.86M	$2.96B	$6.44B	$12.38B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-0.11	18.43	24.66	23.99
Price / Sales	N/A	326.44	527.00	106.82
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	0.21	4.11	10.75	6.50
Net Income	-$15.81M	$64.45M	$3.56B	$336.88M
7 Day Performance	-29.65%	1.41%	1.00%	-0.14%
1 Month Performance	-32.43%	1.04%	0.43%	0.77%
1 Year Performance	-63.81%	23.88%	29.69%	28.49%

Quoin Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNRX Quoin Pharmaceuticals	1.1784 of 5 stars	$3.25 -26.3%	N/A	-62.1%	$8.86M	N/A	N/A	4	News Coverage High Trading Volume
NEPH Nephros	2.1317 of 5 stars	$3.28 +2.8%	$6.00 +83.0%	-23.1%	$35.61M	$18.79M	46.85	30	Positive News
NSPR InspireMD	3.6913 of 5 stars	$0.74 +3.9%	$4.50 +508.1%	-72.2%	$34.66M	$10.85M	N/A	50	Gap Up
MLSS Milestone Scientific	N/A	$0.34 +1.2%	$1.00 +190.7%	-62.7%	$30.43M	$8.90M	N/A	30	Gap Down
PSTV Plus Therapeutics	1.8122 of 5 stars	$4.40 -3.8%	$56.40 +1,183.0%	-11.4%	$30.31M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNRX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. NEPH, NSPR, MLSS, PSTV, and CTSO

How does Quoin Pharmaceuticals compare to Nephros?

Summary

How does Quoin Pharmaceuticals compare to InspireMD?

Summary

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Summary

How does Quoin Pharmaceuticals compare to Plus Therapeutics?

Summary

How does Quoin Pharmaceuticals compare to Cytosorbents?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. NEPH, NSPR, MLSS, PSTV, and CTSO

How does Quoin Pharmaceuticals compare to Nephros?

Which has more volatility & risk, NEPH or QNRX?

Does the media favor NEPH or QNRX?

Is NEPH or QNRX more profitable?

Do insiders & institutionals hold more shares of NEPH or QNRX?

Do analysts prefer NEPH or QNRX?

Which has stronger earnings and valuation, NEPH or QNRX?

Summary

How does Quoin Pharmaceuticals compare to InspireMD?

Is NSPR or QNRX more profitable?

Do analysts recommend NSPR or QNRX?

Which has higher valuation and earnings, NSPR or QNRX?

Do institutionals and insiders hold more shares of NSPR or QNRX?

Which has more risk & volatility, NSPR or QNRX?

Does the media favor NSPR or QNRX?

Summary

How does Quoin Pharmaceuticals compare to Milestone Scientific?

Which has stronger valuation and earnings, QNRX or MLSS?

Do analysts recommend QNRX or MLSS?

Does the media favor QNRX or MLSS?

Which has more risk and volatility, QNRX or MLSS?

Do institutionals & insiders have more ownership in QNRX or MLSS?

Is QNRX or MLSS more profitable?

Summary

How does Quoin Pharmaceuticals compare to Plus Therapeutics?

Do institutionals and insiders believe in PSTV or QNRX?

Is PSTV or QNRX more profitable?

Which has more volatility & risk, PSTV or QNRX?

Do analysts rate PSTV or QNRX?

Which has stronger earnings and valuation, PSTV or QNRX?

Does the media favor PSTV or QNRX?

Summary

How does Quoin Pharmaceuticals compare to Cytosorbents?

Which has preferable earnings & valuation, QNRX or CTSO?

Does the media refer more to QNRX or CTSO?

Is QNRX or CTSO more profitable?

Do institutionals & insiders hold more shares of QNRX or CTSO?

Do analysts recommend QNRX or CTSO?

Which has more volatility & risk, QNRX or CTSO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools